{
  "abstract": "Chemoimmunotherapy (CIT) has significantly improved outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). However, relapses are common. Long-term survival (LTS) is possible for some patients with ES-SCLC treated with CIT regimens; however, the optimal duration for maintenance immunotherapy remains unknown. There is no data on optimal treatment options if LTS patients relapse while off therapy. Here, we are presenting a patient with ES-SCLC, who stopped treatment at 2 years, with disease relapse shortly afterwards. She was treated with a second course of single-agent immunotherapy with another durable remission.",
  "authors": [
    {
      "affiliations": [
        "Internal Medicine, CHI Saint Vincent Health System, Little Rock, Arkansas, USA"
      ],
      "name": "Natalie Shammas"
    },
    {
      "affiliations": [
        "Thoracic Medical Oncology, St. Lukes University Health Network, Bethlehem, Pennsylvania, USA"
      ],
      "name": "Sajjad Bhatti"
    }
  ],
  "title": "Durable response to a second course of immunotherapy in a long-term survivor with relapsed small cell lung cancer",
  "uid": "68460127-788c-5f69-9144-e513a4f887f6"
}